Vivos Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. is a United States-based publicly traded company listed on the NASDAQ under the ticker VVOS. For French-, Belgian- and Swiss-based investors, it sits in the healthcare and life sciences universe, specifically in medical devices and sleep-disorder treatment services. The company was founded in 2016 and is headquartered in Littleton, Colorado, United States. Its strategic positioning is built around a non-invasive, non-surgical, and non-pharmaceutical approach to obstructive sleep apnea (OSA), a large and clinically significant market where standard solutions such as CPAP are not always well tolerated. Vivos’ business model centers on proprietary diagnostic and therapeutic solutions for sleep-related breathing disorders. Its core offerings include oral appliance therapies such as the DNA appliance and the Vivos CARE system, complemented by diagnostic tools including VivoScore. The company has historically targeted dentists and other healthcare professionals trained to deliver its protocols, while more recently expanding its go-to-market model through provider partnerships, sleep-center affiliations, and targeted acquisitions. Management has described this evolution as a pivot toward a more scalable, provider-based distribution strategy. From a competitive standpoint, Vivos operates in a niche but potentially attractive segment at the intersection of dental sleep medicine, respiratory care, and medical devices. Its differentiation lies in positioning itself as an alternative to conventional OSA management, particularly for patients seeking a less invasive option than positive airway pressure devices or surgery. Regulatory and clinical validation matters materially in this space, and Vivos has highlighted FDA clearances for certain products and ongoing clinical data as part of its investment case. That said, the company remains a relatively small player, so execution risk, physician adoption, reimbursement dynamics, and commercialization efficiency remain key variables. Recent developments have been meaningful. In 2025, Vivos announced and completed the acquisition of The Sleep Center of Nevada, described by the company as the largest operator of medical sleep centers in Nevada. Management has framed this transaction as part of a broader national expansion strategy aimed at placing Vivos’ therapies in front of more diagnosed patients and building new revenue streams. The company also reported sequential revenue growth in the third quarter of 2025 and continued to expand its leadership team to support operational scaling. For investors, VVOS remains a higher-risk growth story, but one with a distinct clinical niche and a business model that is still being re-shaped toward potentially more durable distribution and revenue generation.